Comparison between traditional and goal directed perfusion in cardiopulmonary by-pass. A differential cost analysis in US by Povero, Massimiliano & Pradelli, Lorenzo
77Farmeconomia. Health economics and therapeutic pathways 2015; 16(3) © SEEd All rights reserved
Sorin HeartLinkTM is the first and unique 
perfusion system automatically integrating 
perfusion data, patient parameters and pro-
duct information to enable implementation 
of Goal Directed Perfusion (GDP) adapting 
adequacy of perfusion to the patient.
Hypothesis of the Goal dIrected perFusion 
Trial (GIFT) protocol is that a GDP approach 
can raise this percentage to more than 90% of 
cases, with a consequent reduction in the AKI 
rate of about 40% [3].
Aim of this project is to perform an econo-
mic evaluation of the consequences of GDP 
strategy in US, through the construction, va-
lidation, and analysis of an ad hoc simulation 
model based on estimation of goal-achieve-
ment rate (DO2 value over the threshold of 
272 ml/min/m2) with and without GDP and 
the correlations between main clinical out-
IntroductIon
Oxygen delivery (DO2) and carbon dioxide 
production (VCO2) during cardiopulmonary 
bypass (CPB) are associated with renal out-
come in cardiac surgery [1,2]. Nadir DO2 be-
low the threshold of 262-272 ml/min/m2 and 
DO2/VCO2 ratio lower than 5.0 are linked to 
an increased incidence of acute kidney injury 
(AKI) after cardiac operations [1].
Data collected in [2] shows that 693 patients 
reached the DO2 target among 1,048 patients 
undergoing CPB with a traditional perfusion 
strategy. Such patients were divided in two 
groups according to HCT level; as anticipa-
ted by physiology (see Appendix A), results 
show that the probability to achieve the DO2 
goal resulted higher among patients with 
HCT> 26% (640 of 753 patients) than in pa-
tients with HCT< 26% (53 of 293 patients).
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AbstrAct
OBJECTIVES: High oxygen delivery (DO2) during cardiopulmonary bypass (CPB) is associated with better renal outcome 
in cardiac surgery. Traditional perfusion (TP) techniques, targeted on body surface area and CPB temperature, achieves 
high DO2 in about 50% of the cases while a goal directed perfusion (GDP) approach can lead to more than 90% of cases 
achieving high DO2 with a consequent reduction in Acute Kidney Injury (AKI) rate of about 40%. Aim of this study is 
to perform an economic evaluation of GDP strategy with respect to TP in US. METHODS: A Discrete Event Simulation 
model was developed to compare TP and GDP strategy in patients undergoing CPB. The patient’s pathways from operation 
to discharging from hospital was simulated: AKI incidence, in-hospital mortality, hospital length of stay, transfusions were 
correlated to probability to achieve high DO2 target using published correlations. National perspective was adopted to cal-
culate costs associated to each event while GDP strategy was exploited the introduction of Sorin Heartlink (HL) Card/GDP 
Card and Sorin Connect (electronic data management system). RESULTS: GDP strategy saved more than 3 days in hospital 
and 11% of AKI episodes. The cost-saving is $ 3,137 (95% CI: 1,122-4,951); the cost of HL Card/GDP Card+Connect ($ 
180, 95% CI: 113-249) is more than offset by savings in hospital stay that result the main driver in cost ($ 3,222, 95% CI: 
1,235-4,950). Deterministic sensitivity analysis shows that the total savings are mainly influenced by nadir haematocrit 
during CPB and hospital LOS/cost per day both in ICU and in ward. CONCLUSIONS: GDP seems to improve significantly 
the main outcomes related to CPB surgery, when compared to TP techniques. Additional costs due to perform GDP strategy 
have no impact on the total cost since completely offset by the savings in hospital cost. 
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comes (AKI incidence, in-hospital mortality, 
hospital length of stay, transfusions) and DO2 
over the critical threshold. All possible patient 
pathways during the peri- and post-operative 
period were considered in order to estimate 
management of adverse events, hospital stay 
and related resource consumption costs.
Methods
Model structure
A patient-level simulation model was deve-
loped incorporating baseline outcomes rates 
and comparative efficacy data from publi-
shed literature, and US hospital cost data.
The model simulates two treatment alternati-
ves for patients undergoing CPB: traditional 
perfusion (TP – targeted on BSA and CPB 
temperature) and goal-directed perfusion 
(GDP – specifically aimed at maintaining 
DO2 over the critical threshold). GDP is al-
lowed by an integrated monitoring system 
(Sorin GDPTM Monitor) displaying DO2 and 
DO2/VCO2 values in a quasi-continuous 
mode: the perfusionist can immediately react 
to lowering DO2 by increasing pump flow, as 
a primary intervention.
The model was structured as a decision 
analytic Discrete Event Simulation (DES); in 
a DES changes in the individuals’ state are 
modelled over time, in terms of events that 
occur and their consequences. This strategy 
is preferable to the Markov methodology in 
representing clinical conditions that are nei-
ther chronic nor characterized by recurrent 
events occurring at fixed time intervals, like 
in patients analysed here.
According to this technique, each iteration 
of the simulation represents a unique patient, 
who is sent simultaneously through both 
treatment arms of the model. The parame-
ters of each iteration are drawn from their 
distributions, allowing representation of the 
individual variability in the outcomes of the 
simulated population. The simulation steps 
are qualitatively common for both treatment 
arms, which however differ in the probability 
of the events considered, and for the time-to-
event distributions.
The patient’s pathway (Table I) is detailed 
below.
During CPB:
 - Each patient is characterized by sampling 
a nadir haematocrit (HCT) value; this is 
independent of the perfusion strategy 
considered.
 - According to the HCT level (> or < 26%), 
patients reach DO2 target with a proba-
bility that depends on the perfusion stra-
tegy.
 - According to transfusion protocol (de-
pending on HCT level) patients can recei-
ve packed red cells (PRCs).
 - Patients are at risk of renal adverse events:
 - AKI, with probabilities depending on 
DO2 level (target reached or not).
 - Renal failure needing RT (only for pa-
tients experiencing AKI) with proba-
bilities that also depend on DO2 level 
(target reached or not).
Post CPB:
 - During the post-operative period, patients 
can die with probability that depends on 
renal complications (AKI or not) and can 
receive PRCs.
 - Post-operative length of stay (LOS) in 
ICU depends on DO2 level during CPB.
 - LOS in ward (only for patients discharged 
alive from ICU) depends on DO2 level 
during CPB.
The hospital perspective was adopted when 
calculating costs associated to each state and 
to evaluate the differential economic impact 
of GDP vs TP. Only potentially differential 
costs were considered in the analyses so the 
total cost calculated in the simulation repre-
sents the sum of these cost items.
Half-cycle correction was applied to LOS in 
ICU and to number of PRCs post-CPB for 
patients dying in ICU.
input parameters
Clinical parameters not 
depending on DO2 level
The lowest haematocrit during CPB was 
taken from a retrospective analysis on data 
from 5,000 consecutive cardiac operations 
with CPB performed on adults (1994 to 
2000) [4]. For each modelled patient, a nadir 
event Depending on
During CPB surgery
Reaching DO2 target HCT, P*
PRCs transfused HCT
Renal disease (AKI) DO2
AKI needing of RT DO2
in iCU (post-CPB)
LOS DO2
PRCs transfused HCT
Death AKI
in ward
LOS DO2
Table i. Events evaluated during the simulation
* perfusion strategy (traditional or GDP)
AKI = acute kidney injury; HCT= nadir haematocrit; LOS = length of stay; PRCs = packed 
red cells
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HCT value was sampled from a gamma di-
stribution fitted on mean and SD reported in 
the article (Table II).
Probability to achieve the DO2 target with 
traditional perfusion was elaborated from [2] 
as explained in the Introduction while for the 
GDP strategy we supposed the 100% of suc-
cess for patients with nadir HCT> 26% du-
ring CPB and 90% otherwise (Table II).
The relationship between AKI incidence and 
post-operative mortality was investigated, 
using logistic regression modelling, in a mul-
ticentre cohort study on 3,500 adult patients 
undergoing cardiac surgery at 7 hospitals du-
ring 2004 [5]. Three thresholds of AKI were 
selected to evaluate mortality rates: > 25%, > 
50%, and > 75% decrease in estimated glo-
merular filtration rate (eGFR) within 1 week 
of surgery. Since in this study eGFR was esti-
mated using the Cockcroft-Gault formula, an 
eGFR decrease greater than 33% coincides 
with the definition of AKI in the GIFT pro-
tocol (i.e. > 50% increase in serum creatini-
ne, see Appendix B for calculation details). 
Assuming that patients with eGFR decrease 
25-50% were uniformly distributed (i.e. one 
third between 25-33% and 2 thirds between 
33-50%), post-operative mortality results in 
11.9% and 1.2% for patients experiencing 
and not experiencing AKI, respectively (Ta-
bel II).
During CPB, according to current practice 
and the GIFT protocol, transfusions are man-
datory below a HCT of 18% and generally 
prohibited for an HCT > 21%. However, ba-
sed on the individual judgment that the pa-
tient is actually in need for packed red cells, 
transfusions are allowed between an HCT 
of 22% and 24%. Transfusions are always 
prohibited for an HCT > 24%. After CPB, 
transfusions are mandatory if HCT < 18%, 
allowed for HCT between 19% and 23% and 
generally prohibited otherwise. However for 
HCT between 24% and 30%, transfusions are 
admitted based on physician’s judgment. In 
order to simulate this uncertainty in the mo-
del, we chose a probability of 50% to be tran-
sfused for allowed transfusions and 25% for 
transfusions admitted based on physician’s 
judgment.
Numbers of PRCs transfused during CPB 
and after CPB (in ICU) were sampled from 
gamma distributions fitted on mean and SD 
reported in [1] and [6], respectively (Table 
II).
Clinical input parameters 
depending on DO2 level
A retrospective analysis of data prospecti-
vely collected at two different institutions [1] 
shows that hospital and ICU length of stay 
(LOS) and renal disease (AKI) are correlated 
with the DO2 level during CPB (Table III). 
Length of stay in ward was calculated star-
ting from hospital and ICU LOS according to 
mortality and AKI rate; in fact the mean value 
of this outcome is not the difference between 
mean time spent in hospital and in ICU, since 
some patients die in ICU (and mortality de-
pends on experiencing or not renal disease).
Risk of renal disease in patients with low 
DO2 during CPB results more than double 
Parameters Values Sources
Nadir HCT on CPB (%) [mean (SD)] 21.4 (4.2) [4]
Probability to achieve DO2 goal (%) high hCT low hCT
With TP 85 18 [2]
With GDP 100 90 Elaborated from [3]
With AKi w/o AKi
 Operative mortality (%) 11.9 1.2 Elaborated from [5], see Table IA in Appendix B
Transfusion protocol During CPB Post CPB (in iCU)
PRC units [mean (SD)] 1.7 (2.0) 1.1 (1.4) Elaborated from [1]*, [6]
Transfusion rate (%) [3]
 • HCT< 19% 100 100 Mandatory
 • HCT< 24% 50 50 PRC allowed
 • HCT< 30% 0 25 Admitted based on physician’s judgment only 
during CPB
 • Other 0 0 PRC prohibited
Table ii. Clinical input values not depending on DO2 level, directly
*Gamma distribution was fitted on median (1) and interquartile range (2) of PRCs to estimate mean and SD used in the model
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storage of patient blood. Unit cost summari-
zed in Table IV, (they were not updated since 
calculated using tariffs).
The cost of GDP strategy was calculated con-
sidering the introduction of Sorin Heartlink 
(HL) Card/GDP Card and Sorin Connect 
(electronic data management system); for 
every cost the worst case (i.e. higher possi-
ble price) was considered: cost of the card 
was $ 150.00 for US and cost of Connect per 
patient, calculated dividing the total hospital 
cost for GDP Monitors (assuming three sy-
stems per hospital) by the number of cases 
per HL Card/GDP Card and the Connect life-
time (10 years), results in $ 29.87.
Simulation technique
Base-case
The simulation technique used for the cal-
culation of base-case results is a so-called 
micro-simulation or patient-level simulation. 
According to this technique, each iteration of 
the simulation represents a unique patient, 
which runs through both arms of the model 
(TP and GDP strategies). The parameters of 
each iteration are drawn from their distri-
butions, allowing the representation of the 
individual variability in the outcomes of the 
simulated population. Patient-level parame-
ters and their distributions are presented in 
Appendix D.
Probabilistic sensitivity analysis
While the micro-simulation takes into ac-
count the variability in the population, the 
probabilistic sensitivity analysis (PSA) al-
lows considering the uncertainty on key pa-
rameters and its effect on the estimated out-
comes. This is obtained by a two level Monte 
Carlo simulation: the inner loop (1,000 itera-
tions) is the patient-level simulation, which 
is averaged and repeated 1,000 times (outer 
loop) to perform PSA on key model parame-
ters. In the absence of reliable data on their 
uncertainty, we set a standard deviation of 
20% of their mean value, and attributed ade-
quate distributions according to the type of 
Cost items Unit cost
Renal replacement therapy ($/day) 978.10
ICU ($/day) 1,303.45
Ward ($/day) 779.98
PRC unit transfused ($) 295.94
Table iV. Unit costs used in the model
the risk in patients reaching the target [1,3]. 
The need for replacement therapy among pa-
tients experiencing AKI, elaborated from [2], 
results about 10% in patients reaching the 
DO2 target, while it is almost 20% in patients 
not reaching the target. Altogether, this im-
plies the hypothesis that low DO2 is associa-
ted with more frequent and also more severe 
renal injury.
Costs were elaborated in a previous analysis 
on patients undergoing aortic valve replace-
ment (AVR) [7]. All of the data are the na-
tional average costs for Medicare discharges 
associated with ICD-9-CM procedure code 
35.22 for fiscal year (FY) 2013 and does not 
include Medicare Advantage health mainte-
nance organizations (HMO) utilization. The 
national costs were calculated using the na-
tional average cost-to-charge ratios for 19 de-
partments published by Medicare in the 2015. 
Statistical outliers were removed at the DRG 
level. Average length of stay overall and bro-
ken out by routine and ICU beds is included.
The cost for a hospital stay was made up of 
the cost of the ICU in which the patient spen-
ds the days immediately after the surgical 
procedure plus the cost of the standard ward 
which hosts the patient after the critical post-
operative phase has been completed. The 
cost of hospital haemodialysis treatment was 
included as a complication cost for patients 
that developed renal failure. It was defined as 
the additional charges/day for continuous re-
placement therapy (CRT) in the ICU to avoid 
double counting in ICU costs. An official 
blood bag tariff was taken as a proxy of the 
real cost for the collection, transportation and 
Parameters high DO2 low DO2 Source
length of stay (days) [mean(SD)]
Total in hospital 12.4 (12.1) 17.6 (14.1) [1]
 • in ICU 2.5 (4.4) 4.2 (8.7) [1]
 • in ward 10.2 (11.4) 13.9 (11.2) Elaborated from hospital/ICU LOS according to 
mortality and AKI rate (see Appendix C)
renal disease – AKi (%) 12.1 29.8 Reported in [3], elaborated from [1]
 • of which needing RT 9.9 18.8 RT rate reported in [2] rescaled to total AKI rate
Table iii. Clinical input values depending on DO2 level
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data (i.e. gamma distributions for costs data 
and beta distributions for probabilities). For 
each cost item, the mean value (depending 
on the selected country) was multiplied by 
a gamma distributed factor with mean 1 and 
SD equal to 20%. The parameters on which 
the PSA is conducted and their distributions 
are presented in Appendix C.
Deterministic sensitivity analysis
A deterministic (one-way) sensitivity 
analysis (DSA) was performed in order to 
test the sensitivity of result to variations of 
base-case estimates. A variation of ±20% was 
considered for each parameter except nadir 
HCT during CPB that varies between -10% 
(to avoid unrealistic lower HCT values) and 
+35% (to take into account higher HCT va-
lues reported in recent surgical series) and 
probability to achieve the DO2 goal (±5%) to 
avoid probabilities higher than 100%.
Further analyses
Since the nadir HCT and the DO2 level are 
the center point of the simulation we studied 
the cost difference (GDP vs. TP strategy) in 
the worst case for GDP efficacy (+35% in 
the distribution of nadir HCT) for different 
values of the probability to achieve the DO2 
target with GDP for patients with HCT < 
26% (such probability was varied between 
20% and 90%).
results
Outcomes and costs resulting from 10,000 
simulated patients are shown in Table V and 
Table VI as mean and 95% confidence inter-
val (calculated from PSA).
In the GDP strategy more than 90% of patients 
reach the DO2 target while in TP strategy less 
than 30%. Renal disease incidence is lower 
with respect to traditional perfusion both in 
terms of AKI episodes (11% AKI episodes 
saved) and need for RRT (2.5% dialysis pro-
cedures saved). Reduction in operative mor-
tality (3.6 with TP vs 2.5% with GDP) causes 
the small increment in PRCs transfused (post 
CPB) with GDP strategy; this is due to the 
so called paradox effect: there are more pa-
tients alive in ICU which can be transfused. 
On average, GDP strategy saves more than 3 
days in hospital, of which about 1 ICU day.
Total cost with TP results in about $ 15,300 
while GDP reduces the total cost by more 
than $ 3,000. For both strategies the main dri-
ver is the hospital cost, of which almost one 
third is due to ICU stay. Furthermore, the cost 
of GDP strategy (Sorin GDPTM Monitor and 
Sorin ConnectTM) is completely offset by the 
saving in hospital stay (more than $ 3,000).
Main outcomes reduction, hospital and total 
savings result statistically significant since 
the 95% confidence intervals do not cross the 
zero boundary. Choosing hospital stay reduc-
Outcome [Mean (95% Ci)] TP strategy gDP strategy Delta (gDP vs. TP)
DO2 target achieved (%) 26.9 (19.6-35.4) 91.4 (64.8-100.0) -64.4 (-93.2--36.4)
Hospital stay (days) 16.15 (15.05-17.05) 12.77 (11.22-14.36) 3.38 (1.53-4.99)
 • ICU stay (days) 3.63 (3.16-4.16) 2.52 (2.06-3.14) 1.11 (0.40-1.72)
AKI episode (%) 24.5 (15.7-34.5) 13.6 (6.5-20.7) 10.9 (1.3-21.8)
 • Need for RRT (%) 4.2 (1.8-7.1) 1.7 (0.0-3.1) 2.5 (0.2-5.7)
Operative mortality (%) 3.6 (1.8-5.9) 2.5 (1.1-4.1) 1.1 (-0.2-2.7)
PRC transfused (n.) 2.48 (2.0-2.92) 2.49 (2.0-2.93) 0.01 (0.00-0.01)
Table V. Comparison between traditional and goal directed perfusion: mean results from base case (10,000 simulated patients) while 
the 95% CI is calculated from PSA (1,000 x 1,000 simulation)
Costs ($) [Mean (95% Ci)]
TP strategy gDP strategy Savings (gDP vs TP)
Hospital stay 14,499 (10,098-18,755) 11,276 (7,607-15,060) 3,222 (1,235-4,950)
 • ICU stay 4,737 (2,773-6,772) 3,285 (1,846-4,939) 1,452 (357-2,403)
Renal complication 134 (1-340) 37 (-28-114) 97 (-39-294)
Transfusion 734 (441-1,021) 737 (443-1,025) -3 (-7-1)
GDP monitor* NA 180 (113-249) -180 (-249--113)
Total cost 15,367 (10,985-19,670) 12,230 (8,528-16,055) 3,137 (1,122-4,951)
Table Vi. Resulting cost for traditional and goal directed perfusion: mean results from base case (10,000 simulated patients) while 
the 95% CI is calculated from PSA (1,000 x 1,000 simulation)
*HL Card/GDP Card+Connect
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Analysis on the probability to achieve the 
DO2 target shows that GDP strategy remains 
cost-saving also with worse hypothesis of 
GDP efficacy in a population with higher na-
dir HCT values (Figure 3). In the worst case, 
with a 20% probability of success of GDP 
strategy, a saving of almost $ 400 per case is 
still possible.
dIscussIon
Innovation in the delivery of modern he-
althcare is challenging and profitable; a 
win-win situation where efficient outcomes 
are encountered, is valuable and infrequent. 
Figure 2. Deterministic sensitivity analysis – tornado diagram for saving in US (GDP vs. TP strategy)
Figure 1. Cost-effectiveness plane (GDP vs. TP strategy): red point represent base case simulation result while light blue points are the 
1,000 simulation in the PSA; continuous and dashed lines represent 95% and 99% confidence ellipses, respectively
Figure 3. Savings with respect to different hypothesis of GDP efficacy to achieve DO2 target during CPB in low HCT patients in the worst 
case for GDP efficacy (+35% for nadir HCT distribution). Light red bar represents saving with GDP base case efficacy
tion as effectiveness measure, GDP strategy 
results cost-effectiveness in more than 95% 
of cases (Figure 1). In particular both 95% 
and 99% confidence ellipses lie in the first 
quadrant of the cost-effectiveness plane (less 
hospital stay and more cost savings), comple-
tely.
Total saving is mostly influenced by nadir 
haematocrit and, to a lesser extent, by hospi-
tal length of stay and hospital cost per day, 
both in ICU and ward (Figure 2). In particu-
lar DSA results show that GDP is more cost-
saving for patients with lower nadir HCT, for 
longer hospital stays and in structures with 
higher hospital costs.
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In summary, savings on the microlevel, pa-
tient level or operating theater level, or ma-
crolevel (regional or national) could be con-
siderable.
Estimated results seem comparable with pre-
vious economic analyses. A recent study [8], 
analyzing 953 patients with diabetes mellitus 
and multivessel coronary artery disease un-
dergoing CABG with standard techniques, 
estimates a total cost of about $ 19,500 (exclu-
ding precedural costs and physician fees not 
considered in this analysis); value calculated 
in [8] is higher since it includes also ancillary 
services. In a less recent paper [9], the direct 
costs for 4698 patients undergoing CABG at 
5 US hospital amount to $ 12,800; a lower 
results may be due to a shorter hospital LOS 
(8.7 days). Other two studies reported a mean 
cost (excluding physician fees) of $ 15,713 
[10] and $ 20,574 [11] (2000 US dollars).
conclusIon
Few interventions have positive impact on 
clinical outcomes and costs. This economic 
forecast suggests that even when the probabi-
lity of achieving DO2 goal with GDP is chal-
lenged below plausible values, GDP remains 
a cost-effective strategy. Thus, early uptake 
of such innovative intervention is endorsed 
until such benefits are empirically quantified 
and cost savings are realized. Furhtermore, 
saving is mostly influenced by hospital LOS, 
cost per day both in ICU and in ward, and 
nadir HCT during CPB and additional costs 
due to perform GDP strategy have no impact 
on the total cost since completely offset by 
the savings in hospital cost.
Just by delivering the right information at the 
right time during surgery, directing perfusion 
decisions, undesirable and costly clinical 
outcomes could be avoided. Assuming that 
with GDP, compared to TP, the probability 
to achieve DO2 goal would dramatically in-
crease, on average $ 3,137 per patient (95% 
CI: 1,122-4,951) could be saved. On avera-
ge 3.38 ward days (95% CI: 1.53-4.99) and 
1.11 ICU days (95% CI: 0.40-1.72) would be 
avoided per patient. Hence, the intuitive cost 
driver, intervention cost, was offset mainly by 
the avoided costs of hospital stay. Reducing 
the incidence of AKI episodes, and then the 
need for RRT, also impacted the encountered 
savings but to a much lesser extent.
Presented sensitivity analysis confirms the 
cost-effectiveness of GDP. In the DSA, when 
input parameters were varied to a minimum 
and a maximum value, the total savings per 
patient remained in favour of GDP. This sa-
vings was more sensitive by the HCT values 
as the expected gain is expected to be more 
with those lower HCT values. Then, ward and 
ICU stays/costs also impacted the amount of 
savings. All other input clinical parameters 
like probability of achieving DO2 targets 
or hospital mortality do not seem to impact 
the economic outcomes. Similiarly, assumed 
cost drivers related to AKI or PRC unit perfu-
sion have ignorable impact. Furthermore, in 
order to invistigate the relationship between 
the probability of achieving DO2 goal with 
GDP when HCT distribution is assumed to be 
35% above the base case value: the expected 
benefit is lower ($ 1,378), we varied this pro-
bability from 90% to as low as 20% and the 
cost savings was still realizable.
Analysis on the probability to achieve the 
DO2 target shows that GDP strategy remains 
cost-saving also with worse hypothesis of 
GDP efficacy in a population with higher na-
dir HCT values (Figure 3). In the worst case, 
with a 20% probability of success of GDP 
strategy, a saving of almost $ 400 per case is 
still possible.
dIscussIon
Innovation in the delivery of modern he-
althcare is challenging and profitable; a 
win-win situation where efficient outcomes 
are encountered, is valuable and infrequent. 
Figure 2. Deterministic sensitivity analysis – tornado diagram for saving in US (GDP vs. TP strategy)
Figure 1. Cost-effectiveness plane (GDP vs. TP strategy): red point represent base case simulation result while light blue points are the 
1,000 simulation in the PSA; continuous and dashed lines represent 95% and 99% confidence ellipses, respectively
Figure 3. Savings with respect to different hypothesis of GDP efficacy to achieve DO2 target during CPB in low HCT patients in the worst 
case for GDP efficacy (+35% for nadir HCT distribution). Light red bar represents saving with GDP base case efficacy
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AppendIx A
The DO2 formula
DO2 is the amount of oxygen delivered to the whole body from the lungs/oxygenators. It is defined by the formula
where Qb is the total blood flow or cardiac output, HCT is the haematocrit level, is the arterial saturation, is the arterial 
tension and 0.003 is the solubility coefficient of oxygen in human plasma.
AppendIx b
relation between serum creatinine and egFr
In the GIFT protocol, AKI is defined according to AKIN criteria [12] as:
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where Sc
PO
 is the post-operative serum creatinine and Sc
B
 is the value at baseline. In [5] AKI is defined as a decrease 
greater than 50% in eGFR within one week of surgery, that is:
where eGFR is calculated at baseline (B) and post CPB (PO). We find the relation between definitions (EQ 1) and 
(EQ 2); since eGFR in [5] is estimated using the Cockcroft-Gault formula [13] we have:
where Sc is the serum creatinine valued expressed in mg/dl, the age is measured in years and W is the real weight if 
BMI is normal (between 18.5 and 25) otherwise is calculated as the ideal BMI (18.5 if BMI < 18.5 and 25 if BMI > 
25) multiplied by the square of height.
For each patient, we can consider age and weight constant since the observational time is about a week, than (EQ 3) 
is simply:
where the constant A contains all information on age, weight and sex.
Using definition (EQ 4), we can re-write (EQ 2) for a general reduction β:
If we want , we have to fix β=33%.
Using this threshold we can calculate mortality rate for patient experiencing and not experiencing AKI from analysis 
reported in [5].
Decrease in egFr (%) Deaths (n.) Patients (n.) AKi episode Mortality rate (%)
< 25% 25 2631
nO 1.2
25-50% 25 601
25-33% 8 200
YeS 11.9
33-50% 17 401
50-75% 12 109
> 75% 46 119
Table iA. Elaboration of post-operative mortality based on [5]
AppendIx c
Calculation of the length of stay distribution in ward (post iCU)
For each simulated patient, the total time spent in hospital is defined as the sum of LOS in ICU and LOS in ward (if 
patient was discharged alive from ICU). Furthermore, according to our model, mortality in ICU depends on experien-
cing an AKI episode. Figure 1A shows the decisional tree for calculation of hospital LOS, the structure is the same 
both for patient achieving and not achieving the DO2 target.
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The distribution of LOS in ward was calculated using bootstrap method:
 - 10,000 patients were simulated (both with DO2 target achieved and not achieved) sampling AKI rate, mortality 
and LOS in ICU from distributions fitted on data reported in Table I and Table II. 
 - Time spent in ward was sampled from a gamma distribution with parameters ɑ and β unknown. 
 - ɑ and β was calculated imposing that the resulting hospital LOS distribution was a gamma distribution fitted on 
mean and SD reported in Table II.
AppendIx d
Parameter distributions
Figure 1A. Decisional tree for calculation of hospital length of stay
Mean SD α λ* Distribution
Haematocrit 21.4 4.2 20.19 74.16 Beta
iCU length of stay
High DO2 2.5 4.4 0.32 7.74 Gamma
Low DO2 4.2 8.7 0.23 18.02 Gamma
Ward length of stay
High DO2 10.39 11.45 0.82 12.63 Gamma
Low DO2 14.60 11.01 1.76 8.30 Gamma
Unit transfused
During CPB 1.7 2.0 0.72 2.35 Gamma
Post CPB 1.1 1.4 0.60 1.80 Gamma
Table iiA. Parameters and distribution sampled in the base case simulation (patients-level parameters)
*For beta distribution, the second parameters is usually named β
Prob. to achieve 
DO2 goa
Mean SD α β Mean SD α β
Distribution
TP strategy gDP strategy
HCT> 26% 85 17 2.90 0.51 beta
HCT< 26% 18 3.6 20.32 92.57 90 18 1.60 0.18 beta
high DO2 low DO2
Incidence AKI (%) 12.1 2.42 21.85 158.76 29.8 5.96 17.25 40.64 beta
% AKI needing RT 9.9 1.98 22.43 204.10 18.8 3.76 20.11 86.87 beta
Transfusion rate (%) During CPB Post CPB
HCT< 24% 50 10 12.00 12.00 50 10 12.00 12.00 beta
HCT< 30% 25 5 18.50 55.50 beta
With AKi w/o AKi
Operative mortality (%) 25.4 5.08 18.39 53.89 1.5 0.31 24.60 1,565 beta
Table iiiA. Parameters and distribution sampled in the PSA (outer loop parameters)
